Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CYNK-001 |
Synonyms | |
Therapy Description |
CYNK-001 (taniraleucel) consists of allogeneic CD56+/CD3- natural killer cells expanded from CD34-positive placental stem cells, which may induce cytotoxicity against tumor cells and potentially demonstrates anti-tumor activity (Neuro-Oncology, Vol. 21, Issue Suppl_6, Nov. 2019, Page vi85, EXTH-16). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CYNK-001 | Taniraleucel|CYNK001|CYNK 001 | CYNK-001 (taniraleucel) consists of allogeneic CD56+/CD3- natural killer cells expanded from CD34-positive placental stem cells, which may induce cytotoxicity against tumor cells and potentially demonstrates anti-tumor activity (Neuro-Oncology, Vol. 21, Issue Suppl_6, Nov. 2019, Page vi85, EXTH-16). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04309084 | Phase Ib/II | CYNK-001 | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT04310592 | Phase I | Cyclophosphamide + Fludarabine CYNK-001 | Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01) | Recruiting | USA | 0 |
NCT05218408 | Phase Ib/II | Cyclophosphamide + Fludarabine CYNK-001 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (CYNK001GBM02) | Withdrawn | 0 |